Reality Check on Cystic Fibrosis
Market access for cystic fibrosis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, almost 45% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In October 2019, the FDA approved Vertex Pharmaceuticals Inc.’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people at least 12 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene. The product is the fourth CF therapy from the company and its first triple combination therapy
- Key Findings: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators (Vertex Pharmaceuticals’ Trikafta, Symdeko, Orkambi and Kalydeco) are the first type of CF therapy to treat the root cause of the disease rather than the symptoms. Although costly, these therapies have made a large impact on market value
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.